Johnson & Johnson's Q3 2026 Earnings: What to Expect

New Brunswick, New Jersey-based Johnson & Johnson (JNJ), researches, develops, manufactures, and sells healthcare products across the innovative medicine and medtech sectors. With a market cap of $655.4 billion, the company offers prescription pharmaceuticals, diagnostic equipment, surgical instruments, and medical devices. The healthcare giant is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Tuesday, Oct. 13.

Ahead of the event, analysts expect Johnson & Johnson to report a profit of $2.96 per share on a diluted basis, up 5.7% from $2.80 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. 

For the full year, analysts expect Johnson & Johnson to report EPS of $11.61, up 7.6% from $10.79 in fiscal 2025. Its EPS is expected to rise 10.5% year over year to $12.83 in fiscal 2027. 

JNJ stock has outperformed the S&P 500 Index’s ($SPX) 15.7% gains over the past 52 weeks, with shares up 51.3% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 26.4% gains over the same time frame.

JNJ has outpaced the broader market as robust growth in its Innovative Medicine division, sustained MedTech momentum, and improving full-year earnings expectations have renewed investor confidence. A key driver of this optimism is the milestone FDA De Novo authorization for its OTTAVA™ Robotic Surgical System, the world’s first table-integrated soft tissue robotic platform cleared for multiple general surgery procedures. By securing regulatory clearance across high-volume surgeries like gastric bypass, gastrectomy, cholecystectomy, and hernia repairs, JNJ significantly strengthens its competitive position in the rapidly expanding soft-tissue robotics market, complementing steady pharmaceutical top-line gains to reinforce long-term earnings growth. 

Analysts’ consensus opinion on JNJ stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 25 analysts covering the stock, 14 advise a “Strong Buy” rating, three suggest a “Moderate Buy,” and eight give a “Hold.” JNJ’s average analyst price target is $281.08, indicating a potential upside of 3.4% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.